Il-Mi Okazaki

Il-Mi Okazaki

Auto-generated profile, based on publicly available information

Il-Mi Okazaki

Laboratory of Molecular Immunology, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2007 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YMYuko Matsumoto
Yuko Matsumoto
HMHiroyuki Marusawa
Hiroyuki Marusawa
KKKazuo Kinoshita
Kazuo Kinoshita
YEYoko Endo
Yoko Endo
TKTadayuki Kou
Tadayuki Kou
TCTsutomu Chiba
Tsutomu Chiba

13 September 2020 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
TMTakumi Maruhashi
Takumi Maruhashi
DSDaisuke Sugiura
Daisuke Sugiura
IOIl-Mi Okazaki
Il-Mi Okazaki
TOTaku Okazaki
Taku Okazaki
To prevent the destruction of tissues owing to excessive and/or inappropriate immune responses, immune cells are under strict check by various regulatory mechanisms at multiple points. Inhibitory coreceptors, including programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4), serve as critical checkpoints in restricting immune responses against self-tissues and tumor cells. Immune checkpoint inhibitors that block PD-1 and CTLA-4 pathways significantly improved the outcomes of patients with diverse cancer types and have revolutionized cancer treatment. However, response rates to such therapies are rather limited, and immune-related adverse events are also observed in a substantial patient population, leading to the urgent need for novel therapeutics with higher efficacy and lower toxicity. In addition to PD-1 and CTLA-4, a variety of stimulatory and inhibitory coreceptors are involved in the regulation of T cell activation. Such coreceptors are listed as potential drug targets, and the competition to develop novel immunotherapies targeting these coreceptors has been very fierce. Among such coreceptors, lymphocyte activation gene-3 (LAG-3) is expected as the foremost target next to PD-1 in the development of cancer therapy, and multiple clinical trials testing the efficacy of LAG-3-targeted therapy are underway. LAG-3 is a type I transmembrane protein with structural similarities to CD4. Accumulating evidence indicates that LAG-3 is an inhibitory coreceptor and plays pivotal roles in autoimmunity, tumor immunity, and anti-infection immunity. In this review, we summarize the current understanding of LAG-3, ranging from its discovery to clinical application.

10 May 2019 in Science
Verified
Journal Article
Closed access
PDF file
DSDaisuke Sugiura
Daisuke Sugiura
TMTakumi Maruhashi
Takumi Maruhashi
IOIl-Mi Okazaki
Il-Mi Okazaki
KSKenji Shimizu
Kenji Shimizu
TMTakeo K. Maeda
Takeo K. Maeda
TOTaku Okazaki
Taku Okazaki
Sparing T cells from inhibition: Programmed cell death 1 (PD-1) is an inhibitory receptor that normally keeps T cell immune responses in check. Immunotherapy targeting PD-1 has proven successful for certain types of cancer, but it remains unclear how PD-1 is regulated. Sugiura et al. found that a costimulatory molecule, CD80, can restrict PD-1 function during the activation of T lymphocytes. Binding of CD80 to the PD-1 ligand PD-L1 in cis on primary activated dendritic cells interfered with the ability of PD-L1 to access PD-1 on T cells, which would otherwise have inhibited T cell activation. Functional insights into PD-L1–CD80 interactions may explain the outcomes of anti–PD-1 and anti–PD-L1 cancer therapy. Science , this issue p. 558

5 May 2003 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
IOIl-Mi Okazaki
Il-Mi Okazaki
HHHiroshi Hiai
Hiroshi Hiai
NKNaoki Kakazu
Naoki Kakazu
SYShuichi Yamada
Shuichi Yamada
MMMasamichi Muramatsu
Masamichi Muramatsu
THTasuku Honjo
Tasuku Honjo
Genome stability is regulated by the balance between efficiencies of the repair machinery and genetic alterations such as mutations and chromosomal rearrangements. It has been postulated that deregulation of class switch recombination (CSR) and somatic hypermutation (SHM), which modify the immunoglobulin (Ig) genes in activated B cells, may be responsible for aberrant chromosomal translocations and mutations of non-Ig genes that lead to lymphocyte malignancy. However, the molecular basis for these genetic instabilities is not clearly understood. Activation-induced cytidine deaminase (AID) is shown to be essential and sufficient to induce both CSR and SHM in artificial substrates in fibroblasts as well as B cells. Here we show that constitutive and ubiquitous expression of AID in transgenic mice caused both T cell lymphomas and dysgenetic lesions of epithelium of respiratory bronchioles (micro-adenomas) in all individual mice. Point mutations, but not translocations, were massively introduced in expressed T cell receptor (TCR) and c-myc genes in T lymphoma cells. The results indicate that AID can mutate non-Ig genes including oncogenes, implying that aberrant AID expression could be a cause of human malignancy.

7 February 2011 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TOTaku Okazaki
Taku Okazaki
IOIl-Mi Okazaki
Il-Mi Okazaki
JWJian Wang
Jian Wang
DSDaisuke Sugiura
Daisuke Sugiura
FNFumio Nakaki
Fumio Nakaki
THTasuku Honjo
Tasuku Honjo
Stimulatory and inhibitory co-receptors play fundamental roles in the regulation of the immune system. We describe a new mouse model of spontaneous autoimmune disease. Activation-induced cytidine deaminase–linked autoimmunity (aida) mice harbor a loss-of-function mutation in the gene encoding lymphocyte activation gene 3 (LAG-3), an inhibitory co-receptor. Although LAG-3 deficiency alone did not induce autoimmunity in nonautoimmune-prone mouse strains, it induced lethal myocarditis in BALB/c mice deficient for the gene encoding the inhibitory co-receptor programmed cell death 1 (PD-1). In addition, LAG-3 deficiency alone accelerated type 1 diabetes mellitus in nonobese diabetic mice. These results demonstrate that LAG-3 acts synergistically with PD-1 and/or other immunoregulatory genes to prevent autoimmunity in mice.

14 June 2002 in Science
Verified
Journal Article
Closed access
PDF file
KYKiyotsugu Yoshikawa
Kiyotsugu Yoshikawa
IOIl-Mi Okazaki
Il-Mi Okazaki
TETomonori Eto
Tomonori Eto
KKKazuo Kinoshita
Kazuo Kinoshita
MMMasamichi Muramatsu
Masamichi Muramatsu
THTasuku Honjo
Tasuku Honjo
Activation-induced cytidine deaminase (AID), a putative RNA-editing enzyme, is indispensable for somatic hypermutation (SHM), class switch recombination, and gene conversion of immunoglobulin genes, which indicates a common molecular mechanism for these phenomena. Here we show that ectopic expression of AID alone can induce hypermutation in an artificial GFP substrate in NIH 3T3 murine fibroblast cells. The frequency of mutations was closely correlated with the level of transcription of the target gene, and the distribution of mutations in NIH 3T3 cells was similar to those of SHM in B lymphocytes. These results indicate that AID is sufficient for the generation of SHM in an actively transcribed gene in fibroblasts, as well as B cells, and that any of the required cofactors must be present in these fibroblasts.